Added to YB: 2026-06-12
Pitch date: 2026-06-10
INCY [neutral]
Incyte Corporation
+1.76%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Market Cap
$21.1B
Pitch Price
$105.97
Price Target
N/A
Dividend
N/A
EV/EBITDA
10.97
P/E
14.93
EV/Sales
3.19
Sector
Biotechnology
Category
growth
Show full summary:
GS Healthcare Conference – Recap part 1 (Day 2) - Incyte Corporation
INCY (overview): At $103.38, transitioning from Jakafi dependence to multi-driver heme/oncology platform. Non-Jakafi ~$1.7B run-rate, targeting $3-4B by 2030. 8 pipeline assets; Jakafi XR ($50-75M by end-2026). Key: 9989 mCALR antibody as Jakafi successor, $2-3B peak. M&A score 72, growth 83.
Read full article (1 min)